Global Urinary Incontinence Therapeutics Market Forecast Report, 2019-2023 – Leading Players are Allergan, Astellas Pharma, Merck, Novartis, and Pfizer –

Urinary Incontinence Therapeutics Market 2019-2023”
report has
been added to’s offering.

The Global Urinary Incontinence Therapeutics Market is expected to grow
at a CAGR of 3.12% during the period 2019-2023.

The report has been prepared based on an in-depth market analysis with
inputs from industry experts. The report covers the market landscape and
its growth prospects over the coming years. The report also includes a
discussion of the key vendors operating in this market.

One trend affecting this market is the shift toward novel formulations.
Many novel formulations are being developed for the treatment of urinary
incontinence and they include the trans-dermal therapies and
mechanism-of-action (MoA)-based therapies such as bete-3- adrenergic
agonists and M3 specific anticholinergics.

According to the report, one driver influencing this market is the
robust pipeline for the development of drugs for urinary incontinence
treatment. Most of the urinary incontinence therapeutics that are
currently in Phase III stage are likely to get approved during the
forecast period to augment the growth of the global urinary incontinence
market. Furthermore, the increasing number of molecules being developed
for urinary incontinence treatment will drive the demand for urinary
incontinence therapeutics across the period of forecast.

Further, the report states that one challenge affecting this market is
the patent expiries of drugs. Since generic drugs are copies of branded
drugs, they can be independently developed only after the expiry of
patents of the original products which may impede the growth of the

Key Vendors

  • Allergan
  • Astellas Pharma
  • Merck
  • Novartis
  • Pfizer

Topics Covered

1. Executive Summary

2. Scope of the Report

3. Market Landscape

4. Market Sizing

5. Five Forces Analysis

6. Market Segmentation by Product

7. Customer Landscape

8. Geographic Landscape

9. Decision Framework

10. Drivers and Challenges

11. Market Trends

12. Vendor Landscape

13. Vendor Analysis

For more information about this report visit

Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Urological
Disorders Drugs